Broadwing
1 known investors
Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.
BiotechHealthtechMedical Devices
Founders & leadership
Ne
Not explicitly namedFounder, CEO
Investors · 1
In the news
- Broadwing Capital Launches IT Managed Services Platform with CloudScale365 Acquisitionfinance.yahoo.com · 2025
- Current Broadwing Investments | Broadwing Capital Managementbroadwingcap.com · 2023
- Contact Broadwing Capital | Dallas Based Private Equity Firmbroadwingcap.com · 2022
- Our Investment Strategy | Broadwing Capital Managementbroadwingcap.com · 2022
- Private Equity Firm | About Broadwing Capital Managementbroadwingcap.com · 2022
- Funding Worries Ground Broadwing - TheStreetthestreet.com · 2002